Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
multiple sclerosis
Pharma
Rhapsido ph. 3 in MS combines superior safety with strong efficacy
Novartis' Rhapsido delivered on relapse rate and disease progression with no liver safety signals.
Donavyn Coffey
Oct 26, 2026 11:05am
Novartis teams with Olympian Laviai Nielsen on MS campaign
Sep 3, 2026 2:19pm
Novartis' BTK drug clears ph. 3 in MS sans liver safety signal
Sep 1, 2026 11:10am
Biogen investigated by Italian regulator on ‘market abuse’ claims
May 27, 2026 7:38am
Merck KGaA expects Mavenclad generics to deal serious blow in US
Mar 5, 2026 11:30am
Roche eyes busy 2026 despite Vabysmo miss, Tecentriq flop
Jan 29, 2026 11:23am
